Opthea to Participate in November Investor Conferences

OPT 11.04.2024

Full Press ReleaseSEC FilingsOur OPT Tweets

About Gravity Analytica

Recent News

  • 02.05.2025 - Opthea Investor Day - Melbourne
  • 02.03.2025 - Opthea Investor Day - Sydney
  • 01.28.2025 - Opthea Investor Day - New York City

Recent Filings

  • 01.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 01.13.2025 - EX-99.1 EX-99.1

Virtual Bell Potter Healthcare Conference,November 18, 2024

Jefferies London Healthcare Conference,November 19, 2024

MELBOURNE, AustraliaandPRINCETON, N.J.,Nov. 04, 2024(GLOBE NEWSWIRE) --Opthea Limited(ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two investor conferences inNovember 2024.

Conference details are as follows:

Bell Potter Healthcare Conference
Presentation:Monday, November 18, 2024,3:00 PMAEDT (Virtual)
Presenter:Frederic Guerard, PharmD, CEO,Opthea
The webcast will be accessible under “Events & Presentations” in the Investor Relations section of the Company’s website,www.opthea.com.

Jefferies London Healthcare Conference2024
One-on-One Meetings:Tuesday, November 19, 2024
Participant:Frederic Guerard, PharmD, CEO,Opthea

AboutOpthea

Opthea(ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST,NCT04757636, and ShORe,NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website atwww.opthea.comand follow us onXandLinkedIn.

Authorized for release to ASX byFrederic Guerard, PharmD, CEO

Investor Inquiries

PJ KelleherLifeSci Advisors, LLCEmail:pkelleher@lifesciadvisors.comPhone: 617-430-7579

Media Inquiries

Silvana Guerci-LenaNorthStream Global PartnersEmail:silvana@nsgpllc.com

Join our email database to receive program updates:Tel: +61 (0) 3 9826 0399, Email:info@opthea.comWeb:www.opthea.com

Source:Opthea Limited

Primary Logo

Source: Opthea Limited

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com